Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1

Arthritis Research & Therapy
Yannick AllanoreAndré Kahan

Abstract

Microvascular injury, oxidative stress, and impaired angiogenesis are prominent features of systemic sclerosis (SSc). We compared serum markers of these phenomena at baseline and after treatment with nifedipine in SSc patients. Forty successive SSc patients were compared with 20 matched healthy subjects. All SSc patients stopped taking calcium-channel blockers 72 hours before measurements. Twenty SSc patients were also examined after 14 days of treatment with nifedipine (60 mg/day). Quantitative ELISA was used to measure the serum concentrations of vascular endothelial growth factor (VEGF), soluble VEGF receptor 1 (sVEGFR-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), carbonyl residues, and advanced oxidation protein products (AOPP). The median concentrations of VEGF, sVEGFR-1, sVCAM-1, carbonyl residues, and AOPP were significantly higher in SSc patients than in healthy subjects at baseline. A correlation was found between VEGF concentration and carbonyl residue concentration (r = 0.43; P = 0.007). Nifedipine treatment led to a significant decrease in concentrations of sVCAM-1, carbonyl residues, and AOPP but did not affect concentrations of VEGF and sVEGFR-1. Nifedipine treatment ameliorated endothelium injury in pa...Continue Reading

References

Mar 1, 1992·The Journal of Pathology·R J PrescottP Fielding
Apr 11, 1991·Arthritis and Rheumatism·R D AltmanB A Michel
May 29, 1986·The New England Journal of Medicine·A KahanJ C Roucayrol
Nov 1, 1995·British Journal of Rheumatology·C P DentonC M Black
May 1, 1996·Kidney International·V Witko-SarsatB Descamps-Latscha
Nov 1, 1996·Rheumatic Diseases Clinics of North America·E C LeRoy
Feb 17, 1999·The British Journal of Dermatology·K KikuchiK Tamaki
Apr 20, 2001·The International Journal of Biochemistry & Cell Biology·M Shibuya
Aug 18, 2001·Arthritis and Rheumatism·A E ThompsonJ E Pope
Jun 20, 2002·Journal of Cardiovascular Pharmacology·Masahiro SuganoNaoki Makino
Oct 11, 2002·Free Radical Biology & Medicine·Nilanjana Maulik, Dipak K Das
Apr 18, 2003·Seminars in Arthritis and Rheumatism·Marco Matucci CerinicF Marongiu
Sep 25, 2003·Clinical Rheumatology·Y T KonttinenI Virtanen

❮ Previous
Next ❯

Citations

Jun 12, 2009·Rheumatology·A TyndallU Müller-Ladner
Apr 23, 2013·Arthritis Research & Therapy·Jérôme AvouacYannick Allanore
Jul 19, 2016·Modern Rheumatology·Jing-Ying LuoJing-Jun Zhao
Sep 17, 2010·The Journal of Rheumatology·Jerome AvouacYannick Allanore
Aug 19, 2010·The Journal of Rheumatology·Nicoletta Del PapaGiorgio Lambertenghi Deliliers
Mar 7, 2007·Journal of Clinical Immunology·Jozélio Freire CarvalhoYehuda Shoenfeld
May 15, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Dorothee WeihrauchKirkwood A Pritchard
Feb 6, 2010·Journal of Cellular and Molecular Medicine·Mirko ManettiMarco Matucci-Cerinic
Sep 27, 2012·Rheumatology International·Afsha A Topal, Rachita S Dhurat
Jul 5, 2015·Seminars in Immunopathology·Ellen De Langhe, Rik Lories
May 15, 2013·Arthritis and Rheumatism·Marco Matucci-CerinicFredrick M Wigley
Jul 17, 2010·La Revue de médecine interne·L Josselin-MahrJ Cabane

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.